Topical retinoid preparation Differin Gel 0.1% boosts the efficacy of acne treatment when added to systemic or other topical agents, researchers reported to American Academy of Dermatology.

Study showed that patients considered their acne regimen superior when Differin was included compared to therapy that did not include Differin.

 

“It's important to note that the trial included several different acne treatment strategies, and thus our study population represents the broad range of patients typically seen by practicing dermatologists,” said John E. Wolf, Jr., MD, professor and chairman of the dermatology division at Baylor College of Medicine in Houston, Texas.

For the trial, acne patients were followed for a 12-week period while receiving the treatment prescribed by their individual dermatologist.

All treatment regimens contained Differin® Gel 0.1% either as add-on therapy or part of first-line combination therapy.

The data showed that Differin Gel 0.1% was associated with a dramatic reduction in acne comedones and inflammatory lesions (65%).

“Overall, our results demonstrate that Differin® Gel 0.1%, when combined with many different products, yielded reliable improvements with excellent tolerability and patient satisfaction and can thus be viewed as an ideal topical retinoid preparation,” Dr. Wolf observed.

Acne vulgaris affects roughly 80 percent of young adults and adolescents and is one of the most common reasons for office visits to the dermatologist.

Differin® Gel 0.1% is manufactured by Galderma Pharma.

SOURCE: Dermatology News, American Academy of Dermatology 

 Other news